Healthy Volunteer Male SubjectsPhase 1NCT07156916
A Comparative Bioavailability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tamsulosin Hydrochloride 0.4 mg, Prolonged-release Film-coated Tablets, in Healthy Adult Male Subjects, Under Fasting Conditions
A Phase 1 study testing Tamsulosin (0.4 mg/j) in people with Healthy Volunteer Male Subjects, run by Berlin-Chemie AG Menarini Group at 1 site in Armenia.
Trial summary
The aim of this study is to evaluate the bioequivalence and safety of Tamsulosin hydrochloride 0.4 mg, prolonged-release tablets (Synthon Hispania SL, Spain), compared to Omnic Ocas®, Tamsulosin hydrochloride 0.4 mg, prolonged-release film-coated tablets (Astellas Pharma Europe B.V., the Netherlands), after single… Read more about this study
- Who is it for?
- Ages 18 to 45 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Healthy Volunteer Male Subjects
- What is being tested?
- Tamsulosin (0.4 mg/j)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 46 participants
- Where
- 1 siteArmenia
- Study dates
- 8 Sep 2025to 1 May 2026
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Capable of understanding the informed consent form (ICF) and giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
- Healthy male subjects aged 18 to 45 years inclusive, at the time of signing the ICF, able to tolerate venipuncture.
- Verified diagnosis of being "healthy" according to results of standard clinical, laboratory and instrumental methods of examination.
- Body weight ≥50 kg and ≤ 120 kg, Body Mass Index between ≥18.5 and ≤30.0 kg/m2.
- Non-smokers (for at least 3 months).
- Subjects should be willing to remain abstinent (refrain from heterosexual intercourse) or use double barrier contraception during participation in the study and for 30 days thereafter. Double-barrier contraceptive method: condom used together with spermicidal foam/gel/film/cream/suppository.
Who cannot join
- History or presence of allergies.
- Known hypersensitivity or intolerance to tamsulosin and/or other alpha 1 adreno-receptor antagonists and/or any other excipient of the study drugs.
- History of drug-induced angioedema.
- History, presence or necessity of glaucoma or cataract surgery.
- History or presence of acute or chronic diseases of cardiovascular (including arterial hypotension), bronchopulmonary, nervous, endocrine, reproductive systems (including ejaculation disorders), and also diseases of the gastrointestinal tract, liver (including hepatic insufficiency), urinary tract and kidneys (including renal insufficiency), blood, mental diseases; history of convulsive attacks.
- Acute infectious diseases (e.g. influenza, acute respiratory viral infections incl. COVID-19) less than 4 weeks before the first IMP administration.
Show all 32Show fewer
- The presence of any other condition which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results, or the subject's ability to participate in the study.
- Surgery on the gastrointestinal tract (except appendectomy).
- Deviations from the normal parameters in clinical blood count analysis, biochemical blood analysis, urinalysis.
- History or presence of orthostatic hypotension or syncope.
- Systolic blood pressure measured in a sitting position, less than 100 mmHg or above 130 mmHg and/or diastolic blood pressure below 60 mmHg or above 89 mmHg.
- Heart rate less than 60 or more than 80 beats per minute.
- Deviation on the ECG intervals and heart rate or ECG morphology.
- Positive test results for HIV or hepatitis B or C or syphilis at screening.
- Positive test result for cotinine in the urine at screening or before randomisation.
- Positive screen for drugs or alcohol at screening or before randomisation.
- Known or suspected drug or alcohol abuse as judged by the Investigator.
- Alcohol consumption more than 10 units of alcohol a week (1 unit equivalent to 200 ml of dry wine or 50 ml of strong alcoholic drinks or 500 ml of beer) during the six months prior to the first administration of the IMP.
- Intake of xanthine containing substances (e.g., coffee, tea, chocolate, energy drinks, cola) as well as citrus fruits (grapefruit, grapefruit juice etc.) and cranberry (including juices, fruit drinks, etc.) within the last 72 hours before the IMP administration.
- Administration of medicines that have a significant effect on circulatory dynamics, liver function, etc. (barbiturates, omeprazol, cimetidin, NSAIDs, ACE inhibitors, angiotensin II receptor antagonists, diuretics, etc.) less than 2 months or 5 half-lives (whatever is longer) before screening.
- The use of depot-forms of any drugs for 3 months or 5 half-lives (whatever is longer) before screening.
- Use of any prescribed or non-prescribed medication, herbal remedies, vitamins and minerals during the two weeks prior to the first administration of the IMP or longer (at least 5 elimination half-lives) if the medication has a long half-life.
- Mental, physical and other reasons that do not allow the subjects according to investigator's opinion to assess their behavior adequately, to follow correctly the requirements of the clinical study protocol and to assess the expected risks and possible discomfort.
- Dehydration (e.g. due to diarrhea, vomiting, or other causes) within the last 48 hours before the IMP administration.
- Subjects who have been on a special diet (for whatever reason, e.g. vegetarians or hypocaloric diet [less than 1000 cal/day]) during the 28 days prior to the first IMP administration and intention to maintain the diet during the study.
- Intention to perform excessive physical activities during the trial.
- Plasma donation within one month from screening or blood donation/blood loss >500 ml within 3 months before screening.
- Unwillingness or inability to follow the procedures and restrictions outlined in the protocol and the ICF.
- Participation in another clinical study within 3 months before the first IMP administration.
- Difficulty swallowing tablets or fasting or consuming standard meals.
- Any reason in the opinion of the Investigator, would prevent the subject from participating in the study.
- Scheduled to have vaccination during the study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Armenia1 site, 1 recruiting
- Recruiting
"Tonus-Les" LLC
Yerevan, Ankuk Region, 0037
Shougher Heboyan, MD, +374 936656 ext. 67, shogherheboyan@mail.ru
About this study
Official title: A Prospective, Randomised, Open Label, Single Dose, Two-treatment, Two-period, Two-sequence, Crossover Bioequivalence Study of Tamsulosin Hydrochloride 0.4 mg, Prolonged-release Tablets (Synthon Hispania SL, Spain) Versus the Reference Drug Omnic Ocas®, Tamsulosin Hydrochloride 0.4 mg, Prolonged-release Film-coated Tablets (Astellas Pharma Europe B.V., the Netherlands), in Healthy Adult Male Subjects, Under Fasting Conditions
The aim of this study is to evaluate the bioequivalence and safety of Tamsulosin hydrochloride 0.4 mg, prolonged-release tablets (Synthon Hispania SL, Spain), compared to Omnic Ocas®, Tamsulosin hydrochloride 0.4 mg, prolonged-release film-coated tablets (Astellas Pharma Europe B.V., the Netherlands), after single dose administration in healthy adult male subjects under fasting conditions.
Read the detailed description
In this Phase I study, the test medication Tamsulosin hydrochloride 0.4 mg, prolonged-release tablets (Synthon Hispania SL, Spain) is compared to the reference medication (Omnic Ocas®, Tamsulosin hydrochloride 0.4 mg, prolonged-release film-coated tablets by Astellas Pharma Europe B.V., the Netherlands) in terms of bioequivalence of the the tested formulations under fasting conditions.
- Conditions
- Healthy Volunteer Male Subjects
- Being tested
- Tamsulosin (0.4 mg/j)
- Keywords
- Bioequivalence, Tamsulosin
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Tamsulosin (0.4 mg/j)Drug
Prolonged-release tablets 0.4 mg (Synthon Hispania SL, Spain)
Tamsulosin (0.4 mg/j)Drug
Prolonged-release, film-coated tablets (Astellas Pharma B.V., the Netherlands)
| Study group | Role | What they receive |
|---|---|---|
| Tamsulosin 0.4 mg prolonged-release tablets (Synthon Hispania SL, Spain) | Experimental | Single dose administration (0.4 mg) with 240ml of water under fasting conditions Receives: Drug: Tamsulosin (0.4 mg/j) |
| Omnic Ocas®, Tamsulosin hydrochloride 0.4 mg, prolonged-release film-coated tablets (Astellas Pharma | Active comparator | Single dose administration (0.4 mg) with 240 ml of water under fasting conditions. Receives: Drug: Tamsulosin (0.4 mg/j) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cmax
Maximum plasma concentration
Measured: 72 hours
AUC 0-t
Area under the Plasma Concentration Curve from Administration to Last Observed Concentration at Time t
Measured: 72 hours
AUC 0-inf
Area under the Plasma Concentration Curve Extrapolated to Infinite Time
Measured: Infinity
Secondary outcomes (7)
Tmax
Time to maximum plasma concentration
Measured: 72 hours
t 1/2
Plasma half-life
Measured: 72 hours
λz
Terminal Elimination Rate Constant
Measured: 72 hours
AUC Resid
Residual area
Measured: 72 hours
AUC 0-24
Area under the plasma concentration curve from time 0 to 24 h
Measured: 24 hours
partial AUC 0-12
Partial Area under the Plasma Concentration Curve from time 0 to 12 h
Measured: 12 hours
partial AUC 12-t
Partial Area under the Plasma Concentration Curve from 12 h to Last Observed Concentration at Time t
Measured: 72 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Sep 2025
- Study start8 Sep 2025
- Primary completion1 Mar 2026 (estimated)
- Study completion1 May 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy Volunteer Male SubjectsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Open-label, randomized, single-dose, two-period, two-treatment, two-sequence, crossover bioequivalence study
- Masking
- None (open label)
- Enrolment
- 46 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Berlin-Chemie AG Menarini Group
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Shougher Heboyan, MD, Principal investigator, "Tonus-Les" LLC, 2/1 Varshavyan street. 0037 Yerewan, Armenia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07156916
- Sponsor's protocol ID
- BCAM/23/Tam-BE/003
- Status last verified
- Aug 2025
- First submitted
- 27 Aug 2025
- Last updated
- 3 Oct 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: No publication in an ICMJE journal is planned
Study at a glance
From the registry record, last updated by the sponsor on 3 Oct 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective, Randomised, Open Label, Single Dose, Two-treatment, Two-period, Two-sequence, Crossover Bioequivalence Study of Tamsulosin Hydrochloride 0.4 mg, Prolonged-release Tablets (Synthon Hispania SL, Spain) Versus the Reference Drug Omnic Ocas®, Tamsulosin Hydrochloride 0.4 mg, Prolonged-release Film-coated Tablets (Astellas Pharma Europe B.V., the Netherlands), in Healthy Adult Male Subjects, Under Fasting Conditions
- ClinicalTrials.gov ID
- NCT07156916
- Acronym / sponsor ID
- BCAM/23/Tam-BE/003
- Conditions
- Healthy Volunteer Male Subjects
- Keywords
- Bioequivalence, Tamsulosin
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 46 participants (estimated)
- Lead sponsor
- Berlin-Chemie AG Menarini GroupIndustry (pharma, biotech, devices)
- Study start
- 8 Sep 2025 (actual)
- Primary completion
- 1 Mar 2026 (estimated)
- Study completion
- 1 May 2026 (estimated)
- First posted
- 5 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to evaluate the bioequivalence and safety of Tamsulosin hydrochloride 0.4 mg, prolonged-release tablets (Synthon Hispania SL, Spain), compared to Omnic Ocas®, Tamsulosin hydrochloride 0.4 mg, prolonged-release film-coated tablets (Astellas Pharma Europe B.V., the Netherlands), after single dose administration in healthy adult male subjects under fasting conditions.
Detailed description
In this Phase I study, the test medication Tamsulosin hydrochloride 0.4 mg, prolonged-release tablets (Synthon Hispania SL, Spain) is compared to the reference medication (Omnic Ocas®, Tamsulosin hydrochloride 0.4 mg, prolonged-release film-coated tablets by Astellas Pharma Europe B.V., the Netherlands) in terms of bioequivalence of the the tested formulations under fasting conditions.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Open-label, randomized, single-dose, two-period, two-treatment, two-sequence, crossover bioequivalence study
| Arm | Type | Receives |
|---|---|---|
| Tamsulosin 0.4 mg prolonged-release tablets (Synthon Hispania SL, Spain) | Experimental | Drug: Tamsulosin (0.4 mg/j)Single dose administration (0.4 mg) with 240ml of water under fasting conditions |
| Omnic Ocas®, Tamsulosin hydrochloride 0.4 mg, prolonged-release film-coated tablets (Astellas Pharma | Active comparator | Drug: Tamsulosin (0.4 mg/j)Single dose administration (0.4 mg) with 240 ml of water under fasting conditions. |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Capable of understanding the informed consent form (ICF) and giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
- Healthy male subjects aged 18 to 45 years inclusive, at the time of signing the ICF, able to tolerate venipuncture.
- Verified diagnosis of being "healthy" according to results of standard clinical, laboratory and instrumental methods of examination.
- Body weight ≥50 kg and ≤ 120 kg, Body Mass Index between ≥18.5 and ≤30.0 kg/m2.
- Non-smokers (for at least 3 months).
Key exclusion criteria (32 listed)
- History or presence of allergies.
- Known hypersensitivity or intolerance to tamsulosin and/or other alpha 1 adreno-receptor antagonists and/or any other excipient of the study drugs.
- History of drug-induced angioedema.
- History, presence or necessity of glaucoma or cataract surgery.
- History or presence of acute or chronic diseases of cardiovascular (including arterial hypotension), bronchopulmonary, nervous, endocrine, reproductive systems (including ejaculation disorders), and also diseases of the gastrointestinal tract, liver (including hepatic insufficiency), urinary tract and kidneys (including renal insufficiency), blood, mental diseases; history of convulsive attacks.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tamsulosin (0.4 mg/j)Prolonged-release tablets 0.4 mg (Synthon Hispania SL, Spain) | Drug | Omnic Ocas®, Tamsulosin hydrochloride 0.4 mg, prolonged-release film-coated tablets (Astellas Pharma |
| Tamsulosin (0.4 mg/j)Prolonged-release, film-coated tablets (Astellas Pharma B.V., the Netherlands) | Drug | Tamsulosin 0.4 mg prolonged-release tablets (Synthon Hispania SL, Spain) |
Primary outcome
Cmax
Time frame: 72 hours
Maximum plasma concentration
AUC 0-t
Time frame: 72 hours
Area under the Plasma Concentration Curve from Administration to Last Observed Concentration at Time t
AUC 0-inf
Time frame: Infinity
Area under the Plasma Concentration Curve Extrapolated to Infinite Time
7 secondary outcomes
Tmax
Time frame: 72 hours
t 1/2
Time frame: 72 hours
λz
Time frame: 72 hours
AUC Resid
Time frame: 72 hours
AUC 0-24
Time frame: 24 hours
partial AUC 0-12
Time frame: 12 hours
partial AUC 12-t
Time frame: 72 hours
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Oct 2025.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: No. No publication in an ICMJE journal is planned
Related trials for Healthy Volunteer Male Subjects
RecruitingPhase 1
A Randomized, Double-Blind, Positive-Controlled, Parallel Pharmacokinetic Phase I Clinical Study of Cetuximab Injection Versus Erbitux in Healthy Male Subjects
Cetuximab, Bioequivalence
RecruitingPhase 1
Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral Dose
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
RecruitingObservational study
Urinary Vitamin C Loss in Diabetic Subjects
Diabetes
Not yet recruitingPhase 1
Mass Balance Study of [¹⁴C]FXS4640 in Healthy Adult Males
Healthy Subjects
Active, not recruitingPhase 1/2
A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment
Hypothalamic Obesity, Prader-Willi Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Shougher Heboyan, MD principal investigator
"Tonus-Les" LLC, 2/1 Varshavyan street. 0037 Yerewan, Armenia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Tamsulosin (0.4 mg/j) in people with Healthy Volunteer Male Subjects, run by Berlin-Chemie AG Menarini Group at 1 site in Armenia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 32 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 3 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Armenia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Kai Schumacher, MD (+49 (0)30 6707 ext. 2357, kaischumacher@berlin-chemie.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cmax (time frame: 72 hours). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Oct 2025.